Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 13/20 | 0.95 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.95 |
| ▸ | MIF | P14174 | 1/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | GABRP | O00591 | 1/20 | 0.57 |
| ▸ | GABRD | O14764 | 1/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.57 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.57 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.57 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.57 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.57 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.57 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.57 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.57 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.57 |
| ▸ | GABRE | P78334 | 1/20 | 0.57 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine-2,5-Dicarboxylic Acid SCHEMBL9367780 | 1.00 | P4HTM (0.95) | P4HTMP4HA1MIFKDM4EMAPK1 | |
| Pyridine-2,5-Dicarboxylic Acid SCHEMBL29363410 | 0.98 | P4HTM (1.00) | P4HTMP4HA1MIFKDM4EMAPK1 | |
| Pyridine-2,5-Dicarboxylic Acid SCHEMBL70231 | 0.98 | P4HTM (1.00) | P4HTMP4HA1MIFKDM4EMAPK1 | |
| Pyridine-2,5-Dicarboxylic Acid SCHEMBL7655946 | 0.95 | P4HTM (0.95) | P4HTMP4HA1MIFKDM4EMAPK1 | |
| Pyridine-2,5-Dicarboxylic Acid SCHEMBL21173963 | 0.95 | P4HTM (0.95) | P4HTMP4HA1MIFKDM4EMAPK1 | |
| Pyridine-2,5-Dicarboxylic Acid SCHEMBL28522095 | 0.95 | P4HTM (0.95) | P4HTMP4HA1MIFKDM4EMAPK1 | |
| Pyridine-2,5-Dicarboxylic Acid SCHEMBL9341728 | 0.95 | P4HTM (0.95) | P4HTMP4HA1MIFKDM4EMAPK1 | |
| Pyridine-2,5-Dicarboxylic Acid SCHEMBL336436 | 0.95 | P4HTM (0.95) | P4HTMP4HA1MIFKDM4EMAPK1 | |
| Pyridine-2,5-Dicarboxylic Acid SCHEMBL11489139 | 0.95 | P4HTM (0.95) | P4HTMP4HA1MIFKDM4EMAPK1 | |
| Terephthalic Acid SCHEMBL27740483 | 0.95 | P4HTM (0.95) | P4HTMP4HA1MIFKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003688-B2 | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract | IMMUPHARM APS (DK) | 2011-08-23 | — | — | US | disclosed |
| US-7671086-B2 | Pharmaceutical compositions comprising flavonoids and menthol | IMMUPHARM A/S (DK) | 2010-03-02 | — | — | US | disclosed |
| US-20090227670-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL | IMMUPHARM A/S (DK) | 2009-09-10 | — | — | US | disclosed |
| US-7585890-B2 | Pharmaceutical compositions comprising flavonoids and menthol | IMMUNPHARM A/S (DK) | 2009-09-08 | — | — | US | disclosed |
| EP-2089422-A1 | METHODS OF SEPARATING NUCLEIC ACIDS AND PROTEIN | Natimmune A/S (DK) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008106979-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND XYLITOL | IMMUPHARM A/S (DK) | 2008-09-12 | — | — | WO | disclosed |
| CN-100411617-C | Method of treating symptons of common cold allergic rhinitis and infections relating to the respiratory tract | IMMUPHARM APS (DK) | 2008-08-20 | — | — | CN | disclosed |
| WO-2008064686-A1 | METHODS OF SEPARATING NUCLEIC ACIDS AND PROTEIN | NATIMMUNE A/S (DK) | 2008-06-05 | — | — | WO | disclosed |
| EP-1556021-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL | IMMUPHARM AS (DK) | 2007-12-19 | — | — | EP | disclosed |
| US-7166640-B2 | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract | IMMUPHARM APS (DK) | 2007-01-23 | — | — | US | disclosed |
| US-20060148726-A1 | Pharmaceutical compositions comprising flavonoids and menthol | IMMUPHARM A/S C/O NOVI A/S, NIELS JERNES VEJ 10 (DK) | 2006-07-06 | — | — | US | disclosed |
| EP-1307189-B1 | USE OF HYDROXYETHYLRUTOSIDES FOR TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT | IMMUPHARM APS (DK) | 2006-05-10 | — | — | EP | disclosed |
| CN-1717227-A | Pharmaceutical compositions comprising flavonoids and menthol | IMMUPHARM AS (DK) | 2006-01-04 | — | — | CN | disclosed |
| US-20050245467-A1 | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract | IMMUPHARM APS (DK) | 2005-11-03 | — | — | US | disclosed |
| EP-1556021-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL | Immupharm A/S (DK) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004037237-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL | IMMUPHARM A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
| US-20040053858-A1 | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract | IMMUPHARM APS (DK) | 2004-03-18 | — | — | US | disclosed |
| EP-1307189-A2 | METHOD OF TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT | Immupharm APS (DK) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002009699-A2 | METHOD OF TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT | IMMUPHARM APS (DK) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148726-A1 | Pharmaceutical compositions comprising flavonoids and menthol | CHIA, MAVS, C1QBP | P4HTM 3099/4885P4HA1 2170/4885MIF 1244/4885 |
| US-20050245467-A1 | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract | CMA1, CHIA, C1QBP | P4HTM 1696/4885P4HA1 1174/4885MIF 827/4885 |
| US-20040053858-A1 | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract | CMA1, CHIA, C1QBP | P4HTM 1696/4885P4HA1 1174/4885MIF 827/4885 |
| US-20090227670-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL | CHIA, MAVS, C1QBP | P4HTM 3099/4885P4HA1 2170/4885MIF 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.